NASDAQ:CABA Cabaletta Bio (CABA) Stock Price, News & Analysis → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free CABA Stock Alerts $12.08 -0.66 (-5.18%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$11.81▼$12.8150-Day Range$10.48▼$23.9752-Week Range$9.02▼$26.35Volume1.08 million shsAverage Volume1.07 million shsMarket Capitalization$565.46 millionP/E RatioN/ADividend YieldN/APrice Target$34.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Cabaletta Bio alerts: Email Address Cabaletta Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside184.2% Upside$34.33 Price TargetShort InterestBearish21.09% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.82) to ($2.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.67 out of 5 starsMedical Sector831st out of 905 stocksBiological Products, Except Diagnostic Industry143rd out of 154 stocks 3.5 Analyst's Opinion Consensus RatingCabaletta Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCabaletta Bio has only been the subject of 4 research reports in the past 90 days.Read more about Cabaletta Bio's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted21.09% of the outstanding shares of Cabaletta Bio have been sold short.Short Interest Ratio / Days to CoverCabaletta Bio has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous monthShort interest in Cabaletta Bio has recently increased by 16.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCabaletta Bio does not currently pay a dividend.Dividend GrowthCabaletta Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CABA. Previous Next 2.5 News and Social Media Coverage News SentimentCabaletta Bio has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cabaletta Bio this week, compared to 2 articles on an average week.Search Interest36 people have searched for CABA on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Cabaletta Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -85% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cabaletta Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.88% of the stock of Cabaletta Bio is held by insiders.Read more about Cabaletta Bio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cabaletta Bio are expected to decrease in the coming year, from ($1.82) to ($2.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cabaletta Bio is -7.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cabaletta Bio is -7.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCabaletta Bio has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cabaletta Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaElon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Cabaletta Bio Stock (NASDAQ:CABA)Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Read More CABA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CABA Stock News HeadlinesMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cabaletta Bio as CABA-201 Enters RESET Trial with Promising Therapeutic PotentialMay 1, 2024 | americanbankingnews.comCabaletta Bio, Inc. (NASDAQ:CABA) Short Interest UpdateMay 9, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.April 27, 2024 | investing.comCabaletta Bio Inc (CABA)April 18, 2024 | msn.comPhilly-area biotech is worried about Congress’ crackdown on Chinese manufacturersApril 17, 2024 | msn.com🛠️ One Philly rowhouse at a time | Morning NewsletterMarch 23, 2024 | investing.comStifel lifts Cabaletta Bio target to $32 on myositis positionMarch 23, 2024 | finance.yahoo.comCabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash RunwayMay 9, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.March 22, 2024 | markets.businessinsider.comStrong Buy on Cabaletta Bio: Promising CAR T Candidate and Robust Financial OutlookMarch 21, 2024 | markets.businessinsider.comCabaletta Bio Earns ‘Buy’ Rating on Impressive Clinical Progress and Strategic Market PositioningMarch 21, 2024 | investorplace.comCABA Stock Earnings: Cabaletta Bio Misses EPS for Q4 2023March 21, 2024 | msn.comCabaletta gets FDA orphan drug status for systemic sclerosis drugMarch 21, 2024 | finance.yahoo.comCabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 21, 2024 | globenewswire.comCabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 20, 2024 | markets.businessinsider.comCabaletta Bio Says FDA Grants Orphan Drug Designation To CABA-201 To Treat Systemic SclerosisMarch 20, 2024 | finance.yahoo.comCabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic SclerosisMarch 19, 2024 | msn.comA major cog in Philly biotech is in congressional crosshairs for its Chinese ownershipMarch 5, 2024 | msn.comCabaletta Bio Set to Ignite Conversation at Upcoming Health Care ConferencesFebruary 27, 2024 | finance.yahoo.comSeveral Factors Led to the Outperformance of Cabaletta Bio (CABA) in Q4February 27, 2024 | globenewswire.comCabaletta Bio to Participate in Upcoming Investor Conferences in MarchFebruary 21, 2024 | benzinga.comCabaletta Bio Stock (NASDAQ:CABA) Dividends: History, Yield and DatesFebruary 17, 2024 | finance.yahoo.comCABA Mar 2024 35.000 callFebruary 17, 2024 | finance.yahoo.comCABA Mar 2024 30.000 callFebruary 5, 2024 | markets.businessinsider.comStrong Buy Rating for Cabaletta Bio Amid Positive CART Therapy Prospects and Market PotentialFebruary 3, 2024 | msn.comFDA Awards Orphan Drug Designation to Cabaletta's Innovative Myositis TherapyFebruary 2, 2024 | msn.comCabaletta Bio CEO to Speak at Guggenheim's 6th Annual Biotech ConferenceSee More Headlines Receive CABA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/08/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CABA CUSIPN/A CIK1759138 Webwww.cabalettabio.com Phone267-759-3100FaxN/AEmployees101Year FoundedN/APrice Target and Rating Average Stock Price Target$34.33 High Stock Price Target$50.00 Low Stock Price Target$25.00 Potential Upside/Downside+184.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,680,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-40.83% Return on Assets-37.86% Debt Debt-to-Equity RatioN/A Current Ratio15.29 Quick Ratio15.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.51 per share Price / Book2.19Miscellaneous Outstanding Shares46,810,000Free Float42,181,000Market Cap$565.46 million OptionableOptionable Beta2.52 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Steven A. Nichtberger M.D. (Age 63)Co-Founder, Chairman, CEO & President Comp: $970.6kDr. Gwendolyn K. Binder Ph.D. (Age 49)President of Science & Technology Comp: $692.99kDr. David J. Chang FACR (Age 60)M.D., M.P.H., Chief Medical Officer Comp: $676.74kDr. Michael C. Milone M.D.Ph.D., Co-Founder & Co-Chair of Scientific Advisory BoardDr. Aimee Payne M.D.Ph.D., Co-Founder & Co-Chair of Scientific Advisory BoardMr. Anup Marda M.B.A. (Age 46)Chief Financial Officer Comp: $548.2kDr. Samik Basu M.D.Chief Scientific OfficerMr. Michael Gerard J.D. (Age 44)General Counsel & Secretary Ms. Heather Harte-Hall M.Sc.Chief Compliance OfficerMs. Martha O'ConnorChief Human Resources OfficerMore ExecutivesKey CompetitorsExscientiaNASDAQ:EXAIKyverna TherapeuticsNASDAQ:KYTXHumacyteNASDAQ:HUMANovavaxNASDAQ:NVAXPrime MedicineNYSE:PRMEView All CompetitorsInsiders & InstitutionsSwiss National BankBought 8,200 shares on 5/7/2024Ownership: 0.126%Jennison Associates LLCBought 1,796,356 shares on 5/2/2024Ownership: 7.313%Mirae Asset Global Investments Co. Ltd.Sold 11,709 shares on 5/1/2024Ownership: 0.026%China Universal Asset Management Co. Ltd.Bought 3,244 shares on 4/29/2024Ownership: 0.018%CHURCHILL MANAGEMENT CorpSold 2,750 shares on 4/11/2024Ownership: 0.097%View All Insider TransactionsView All Institutional Transactions CABA Stock Analysis - Frequently Asked Questions Should I buy or sell Cabaletta Bio stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CABA shares. View CABA analyst ratings or view top-rated stocks. What is Cabaletta Bio's stock price target for 2024? 9 equities research analysts have issued 12-month target prices for Cabaletta Bio's stock. Their CABA share price targets range from $25.00 to $50.00. On average, they expect the company's share price to reach $34.33 in the next year. This suggests a possible upside of 184.2% from the stock's current price. View analysts price targets for CABA or view top-rated stocks among Wall Street analysts. How have CABA shares performed in 2024? Cabaletta Bio's stock was trading at $22.70 on January 1st, 2024. Since then, CABA shares have decreased by 46.8% and is now trading at $12.08. View the best growth stocks for 2024 here. Are investors shorting Cabaletta Bio? Cabaletta Bio saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 9,870,000 shares, an increase of 16.1% from the March 31st total of 8,500,000 shares. Based on an average daily volume of 954,800 shares, the days-to-cover ratio is currently 10.3 days. View Cabaletta Bio's Short Interest. When is Cabaletta Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CABA earnings forecast. How were Cabaletta Bio's earnings last quarter? Cabaletta Bio, Inc. (NASDAQ:CABA) released its earnings results on Thursday, March, 21st. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.39) by $0.07. What ETFs hold Cabaletta Bio's stock? ETFs with the largest weight of Cabaletta Bio (NASDAQ:CABA) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY).Alger 35 ETF (ATFV). What other stocks do shareholders of Cabaletta Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cabaletta Bio investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Homology Medicines (FIXX), Skyworks Solutions (SWKS), CrowdStrike (CRWD), Precision BioSciences (DTIL), Invitae (NVTA) and Pfizer (PFE). When did Cabaletta Bio IPO? Cabaletta Bio (CABA) raised $87 million in an initial public offering on Friday, October 25th 2019. The company issued 5,800,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group acted as the underwriters for the IPO. Who are Cabaletta Bio's major shareholders? Cabaletta Bio's stock is owned by many different institutional and retail investors. Top institutional investors include Jennison Associates LLC (7.31%), Swiss National Bank (0.13%), CHURCHILL MANAGEMENT Corp (0.10%), Mirae Asset Global Investments Co. Ltd. (0.03%), China Universal Asset Management Co. Ltd. (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Anup Marda, Catherine Bollard, Gwendolyn Binder, Steven Nichtberger and Ventures V LP 5Am. View institutional ownership trends. How do I buy shares of Cabaletta Bio? Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CABA) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithDems have chosen Biden replacement?Paradigm Press348 million Americans lives to END as we know it?The Oxford ClubGold Set to EXPLODE!Gold Safe ExchangeHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.